0001787740 1 2026-09-03 2026-09-03 0001787740 2 2026-09-03 2026-09-03 0001787740 3 2026-09-03 2026-09-03 0001787740 4 2026-09-03 2026-09-03 0001787740 5 2026-09-03 2026-09-03 0001787740 6 2026-09-03 2026-09-03 0001787740 7 2026-09-03 2026-09-03 0001787740 1 2026-09-03 2026-09-03 0001787740 2 2026-09-03 2026-09-03 0001787740 2026-09-03 2026-09-03 iso4217:USD pure S-3 EX-FILING FEES 0001787740 true false N/A S-3 Valion Bio, Inc. false Equity Common Stock, $0.0001 par value per share true 0.0000870 false Equity Preferred Stock, $0.0001 par value per share true 0.0000870 false Debt Debt Securities true 0.0000870 false Other Warrants true 0.0000870 false Other Subscription Rights true 0.0000870 false Other Units true 0.0000870 false Unallocated (Universal) Shelf true 100000000.00 0.0000870 8700.00 100000000.00 8700.00 0.00 8700.00 0.00 This registration statement (“Registration Statement”) covers the registration of such indeterminate number of (a) shares of common stock, (b) shares of preferred stock, (c) debt securities, (d) warrants to purchase shares of common stock, shares of preferred stock or debt securities of the registrant, (e) subscription rights to purchase shares of common stock, preferred stock or debt securities of the registrant and (f) units consisting of any of the aforementioned securities, as may be offered and sold from time to time by the registrant. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the shares being registered hereunder include such indeterminate number of shares of common stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions.<br/><br/>The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act. The aggregate maximum offering price of all securities issued by the registrant pursuant to this Registration Statement will not exceed $100,000,000. The proposed maximum per security and aggregate offering prices per class of securities will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security. true Valion Bio, Inc. S-3 333-269494 2023-02-01 8700.00 Unallocated (Universal) Shelf Unallocated (Universal) Shelf 78947368.42 true Valion Bio, Inc. S-3 333-269494 2023-02-01 11020.00 On February 1, 2023, the registrant filed a registration statement on Form S-3 (File No. 333-269494) with the SEC, which was declared effective on February 8, 2023 (the “2023 S-3”), that registered an aggregate of $100,000,000 of an indeterminate number of securities to be offered by the registrant from time to time, which has expired because more than three years have elapsed since the initial effective date of the 2023 S-3 and all offerings thereunder have been completed or terminated. Of the $100,000,000 of securities registered on the 2023 S-3, for which the registrant paid a filing fee of $11,020, $91,791,980 of the securities remain unsold, leaving $10,115.48 in previously paid fees available for future offset (calculated at the fee rate in effect on the filing date of the 2023 S-3). In accordance with Rule 457(p) under the Securities Act, the registrant is using $8,700 of the aforementioned unused filing fees previously paid by the registrant in connection with its filing of the 2023 S-3 to offset the remaining filing fee payable in connection with this Registration Statement, and as a result of such offset, the registrant will have $1,415.48 remaining in unused filing fees available to be applied to future filings of the registrant in connection with its filing of the 2023 S-3. See Note 1 above.